News: recent publications


Xelstrym to Launch Soon: New FDA-Approved ADHD Stimulant Patch

May 1, 2023A new stimulant medication, Xelstrym (dextroamphetamine), will soon be available for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6-17 and adults 18 and older. Xelstrym is the only transdermal amphetamine patch to be approved by the Food and Drug Administration (FDA). It was presented at the annual conference of the American Professional Society of ADHD and Related Disorders (APSARD) by drug manufacturer Noven Pharmaceuticals, Inc., in January.Xelstrym is a once-daily patch that should be administered two hours before an effect is needed and removed after nine hours.

It has a printed backing on one side and a release liner on the other. Medication is absorbed through the skin via application to the hip, upper arm, chest, upper back, or flank areas.According to a Noven press release distributed on January 10, Xelstrym would be available by the end of March. It is now expected to launch later this year.Xelstrym is available in the following strengths: 4.5mg, 9mg, 13.5mg, and 18mg.

Patients with a known sensitivity to amphetamine products should avoid taking Xelstrym. 1, 2The FDA approved Xelstrym in March 2022, one year after approving the stimulant Azstarys for the treatment of ADHD in people ages 6 and older.Dextroamphetamine is approved for the treatment of narcolepsy and ADHD. U.S.

brand names for dextroamphetamine, besides Xelstrym, include:Xelstrym may help lessen the impact of the lingering Adderall shortage — which began last November and has affected the supplies of other well-known stimulants — however it is also a Schedule II medication subject to regulations by the U.S. Drug Enforcement Administration (DEA). After a $21 billion nationwide opioid settlement, new

. treating adults treating kids News research and news

All articles where News is mentioned
AAP Recommends Mental Health Screening for All U.S. Youth
June 22, 2022Pediatricians should perform mental health screenings on all children and adolescents, evaluating for depression, anxiety, and suicide risk, says a new draft recommendation issued by the American Academy of Pediatrics (AAP).1 A response to the growing mental health crisis among youth, this AAP guidance recommends screening adolescents ages 12 and up for major depressive disorder and youths ages 8 and up for anxiety, even in the absence of documented symptoms.Earlier this year, the AAP recommended universal screening for all kids age 12 and older for suicide risk; for kids aged eight 8 to 11, screening was recommended only when “clinically indicated,” such as when warning signs were present.John Piacentini, Ph.D., a professor of psychiatry and biobehavioral sciences at UCLA, called the AAP draft recommendation important because “anxiety in children is often less easily identified than other disorders, such as ADHD, which can delay treatment.” Left untreated, he said, anxiety is associated with increased risk of depression, self-harm, substance use, and other health risks in later life.The AAP joined the U.S. Preventive Services Task Force (USPSTF) in drafting the screening recommendations and in noting a need for further research on evaluating younger children for mental health conditions.